Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality

被引:28
|
作者
Wang, Yijin [1 ]
Rao, Huiying [2 ]
Chi, Xiumei [3 ]
Li, Boan [4 ]
Liu, Hongyang [1 ]
Wu, Liyuan [1 ]
Zhang, Hao [4 ]
Liu, Shuhong [1 ]
Zhou, Gaungde [1 ]
Li, Na [5 ]
Niu, Junqi [3 ]
Wei, Lai [6 ]
Zhao, Jingmin [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Dept Pathol & Hepatol, Xisihuan Middle Rd 100, Beijing 100039, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Peoples Hosp, Inst Hepatol, Beijing, Peoples R China
[3] Jilin Univ, Hosp 1, Dept Hepatol, Xinmin St, Changchun 130021, Jilin, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Ctr Clin Lab, Beijing, Peoples R China
[5] Adv Cell Diagnost, 3960 Point EdenWay, Hayward, CA 94545 USA
[6] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Litang Rd 168, Beijing 102218, Peoples R China
来源
EBIOMEDICINE | 2019年 / 46卷
基金
中国国家自然科学基金;
关键词
Occult hepatitis C; Direct-acting antiviral agents; RNAscope assay; Liver fibrosis; Hepatic pathology; HEPATITIS-C VIRUS; BLOOD MONONUCLEAR-CELLS; INFECTION; LIVER; RIBAVIRIN; INTERFERON; PEGINTERFERON; SOFOSBUVIR; EFFICACY; THERAPY;
D O I
10.1016/j.ebiom.2019.07.043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Whether achieving sustained virological response (SVR) in patients with hepatitis C attains complete elimination of hepatitis C virus (HCV) is unknown, because occult HCV infection (OCI), defined as the detection of HCV-RNA in hepatocytes or peripheral blood mononuclear cells (PBMC) in absence of serum HCV-RNA, may occur. We thus investigated the prevalence and clinical relevance of OCI. Methods: Subjects from three hospitals who had achieved serum HCV clearance, including 60 of Direct-acting antiviral agents (DAAs) induced SVR, 50 of pegylated interferon plus ribavirin (PR) induced SVR, and 30 of spontaneous resolution, were subjected to detect HCV-RNA in liver by robust RNAscope assay and PBMC by q PCR. Paired liver biopsies at baseline and at SVR24 were analyzed. Results: OCI was detected in 16 of 140 subjects (11.4%), with 15.0% in DAA-based group, 10.0% in PR group and 6.7% in spontaneously resolved group. In DAA-based subgroups, the incidence of OCI was gradually increased in group of solely DAA(s) therapy, combining DAA and PR therapy and combining DAA and ribavirin therapy. OCI is more frequent in patients with genotype 3. No correlation between baseline viral load, interleukin-28B-genotype, baseline transaminases, post-SVR transaminases and OCI were found. However, OCI was significantly linked with severity of fibrosis and active inflammation at post-SVR, even considering basal fibrosis status. In addition, both the magnitude and the frequency of fibrosis regression were lower in patients with OCI than in those without OCI. In the multivariate analysis, PR therapy was identified an independent negative prognostic factor for both hepatic inflammation (P = .022) and fibrosis regression (P = .015). Importantly, we found HCV relapse in one of the Oct patients at 48 weeks after the end of PR treatment. Conclusions: HCV-RNA can persist in hepatocytes and/or PBMC in a certain of patients who achieved spontaneous or treatment-induced HCV RNA clearance from serum and associated with persistent histological abnormality. Our findings provide new insights into cure of HCV and could influence the following-up scenario after SVR. (C) 2019 The Authors. Published by Elsevier B.V.
引用
收藏
页码:227 / 235
页数:9
相关论文
共 50 条
  • [21] mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Kariyama, Kazuya
    Yasuda, Satoshi
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Matono, Tomomitsu
    Nakamura, Shinichiro
    Toyoda, Hidenori
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (06) : 1164 - 1171
  • [22] The incidence of hepatocellular carcinoma in patients with chronic hepatitis C who achieved sustained virological response to interferon therapy
    Kobayashi, S.
    Enomoto, M.
    Tamori, A.
    Kawada, N.
    Habu, D.
    Sakaguchi, H.
    Takedal, T.
    Nishiguchi, S.
    Seki, S.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S219 - S219
  • [23] Does chemotherapy cause hepatitis C viral relapse in cancer patients who achieved sustained virological response?
    Torres, Harrys A.
    Mahale, Parag
    HEPATOLOGY, 2012, 56 : 1048A - 1048A
  • [24] Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response
    Ishido, Shun
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Mori, Nami
    Tsuji, Keiji
    Hasebe, Chitomi
    Mashiba, Toshie
    Ochi, Hironori
    Yasui, Yutaka
    Akahane, Takehiro
    Furuta, Koichiro
    Kobashi, Haruhiko
    Fujii, Hideki
    Ishii, Toru
    Marusawa, Hiroyuki
    Kondo, Masahiko
    Kusakabe, Atsunori
    Yoshida, Hideo
    Uchida, Yasushi
    Tada, Toshifumi
    Nakamura, Shinichiro
    Mitsuda, Akari
    Ogawa, Chikara
    Arai, Hirotaka
    Murohisa, Toshimitsu
    Uebayashi, Minoru
    Izumi, Namiki
    JGH OPEN, 2023, 7 (06): : 424 - 430
  • [25] Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection
    Nirei, Kazushige
    Kanda, Tatsuo
    Nakamura, Hitomi
    Matsuoka, Shunichi
    Takayama, Tadatoshi
    Sugitani, Masahiko
    Moriyama, Mitsuhiko
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2018, 15 (05): : 466 - 474
  • [26] HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin
    Degasperi, Elisabetta
    De Nicola, Stella
    Rumi, Mariagrazia
    D'Ambrosio, Roberta
    JOURNAL OF HEPATOLOGY, 2016, 65 (05) : 1058 - 1059
  • [28] Improvement in immunological abnormalities in patients with chronic hepatitis C who have a sustained virological response to therapy
    Modi, Apurva A.
    Feld, Jordan
    Loomba, Rohit
    Borg, Brian
    Heller, Theo
    Ghany, Marc
    Doo, Edward
    Liang, Jake
    Hoofnagle, Jay
    HEPATOLOGY, 2006, 44 (04) : 341A - 341A
  • [29] Promise and pitfalls of a natural killer cell signature for HCC detection in patients with HCV with sustained virological response
    Moctezuma-Velazquez, Carlos
    Wong, Yu Jun
    Montano-Loza, Aldo J.
    HEPATOLOGY, 2024, 80 (01) : 24 - 26
  • [30] EARLY VIROLOGICAL RESPONSE AND ABSENCE OF DIABETES ARE ASSOCIATED WITH SUSTAINED VIROLOGICAL RESPONSE TO HCV TREATMENT AFTER LIVER TRANSPLANTATION IN PATIENTS WITH CYCLOSPORINE A BASED IMMUNOSUPPRESSION
    Hurtova, M.
    Fourti, M.
    Medjahed, N.
    Samuel, D.
    Neau-Cransac, M.
    Calmus, Y.
    Pageaux, G.
    Lorho, R.
    Vanlemmens, C.
    Laurent, A.
    Decaens, T.
    Duvoux, C.
    LIVER TRANSPLANTATION, 2009, 15 (07) : S131 - S131